What Businesses Should Know About Deconstruction Opportunities in the Coming Weeks St Louis, United States - February ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial” or the "Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...

A Black alderperson called a white alderperson racist, then suggested they settle their differences “outside.” Depending on your point of view, this might have been upsetting or entertaining to those ...

A new publication DOI 10.29026/oes.2026.250031, discusses an integrated metasurface-freeform system enabled multi-focal ...

Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 ...

Teledyne Technologies Incorporated (NYSE:TDY), a global leader in advanced imaging and sensor solutions, is pleased to announce the start of production on multiple awards to deliver state-of-the-art ...

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application from FluoGuide A/S in Copenhagen, Denmark, allowing the company to move forward in the U.S. with a ...

Q4 2025 Earnings Call February 24, 2026 8:00 AM ESTCompany ParticipantsMichael Dale - President, CEO & DirectorLindsey Hartley ...

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this ...

Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 ...

NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended ...

Q4 2025 Earnings Call February 18, 2026 7:00 PM ESTCompany ParticipantsKevin Burke - President, CEO & ChairmanJeffrey ...